Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers (Helping HAND2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01714323|
Recruitment Status : Completed
First Posted : October 25, 2012
Results First Posted : June 8, 2018
Last Update Posted : June 8, 2018
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
Cigarette smoking is the leading preventable cause of death in the U.S. The 2008 US Public Health Service Smoking Cessation Guideline recommends offering effective treatment to smokers in all health care settings, including hospitals. Nearly 4 million smokers are hospitalized each year, and hospital admission offers a "teachable moment" for intervention. Hospital-initiated smoking cessation intervention is effective, but only if contact continues for more than 1 month after discharge. The challenge is to translate this research into clinical practice by identifying an evidence-based cost-effective model that U.S. hospitals can adopt. The major barrier is sustaining contact after discharge. This project tests an innovative strategy to streamline the delivery and maximize the uptake of post-discharge smoking interventions.
Specific Aim: To test the effectiveness of an innovative strategy to maximize smokers' use of evidence-based tobacco treatment (counseling and medication) after hospital discharge, thereby increasing the proportion of smokers who achieve long-term (6-month) tobacco abstinence.
Study Design: A multi-site randomized controlled comparative effectiveness trial will enroll 1350 adult smokers admitted to 3 acute care hospitals in Massachusetts and Pennsylvania. All subjects will receive a brief in-hospital smoking intervention and be randomly assigned at discharge to either Standard Care (passive referral to their state quitline) or Extended Care, a 3-month program consisting of (1) Free Medication: A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider. IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
Outcomes, assessed at 1, 3, and 6 months after hospital discharge, are: (1) intervention effectiveness (cotinine-validated 7-day point-prevalence tobacco abstinence rate at 6 month follow-up [primary outcome] and other tobacco abstinence measures); (2) treatment utilization, and (3) cost-effectiveness (cost per quit). Exploratory analyses will examine the intervention's effect on hospital readmissions and mortality in the 6 months after discharge.
|Condition or disease||Intervention/treatment||Phase|
|Cigarette Smoking Tobacco Smoking Tobacco Use Disorder||Behavioral: Sustained Care Behavioral: Standard Care||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1359 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers|
|Study Start Date :||December 2012|
|Actual Primary Completion Date :||October 2016|
|Actual Study Completion Date :||October 2016|
At discharge, the participant receives the standard care provided by the hospital. This consists of a handout with information to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
Behavioral: Standard Care
Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
Experimental: Sustained Care
A 3-month program after hospital discharge with these 2 components: (1) Free Medication and (2) Interactive Voice Response (IVR) Triage to Telephone Counseling.
Behavioral: Sustained Care
A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free & Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
- Tobacco Abstinence - 6 Month Follow-up [ Time Frame: 6 months ]Cotinine-validated 7-day point prevalence tobacco abstinence at 6 month follow-up
- Continuous Tobacco Abstinence [ Time Frame: 1 month, 3 months, 6 months ]Continuous tobacco abstinence after hospital discharge assessed by self-report at 1, 3, and 6 months.
- Point Prevalence Tobacco Abstinence [ Time Frame: 1 month, 3 months, 6 months ]7-day point prevalence tobacco abstinence after hospital discharge, assessed by self-report
- Duration of Tobacco Abstinence After Hospital Discharge [ Time Frame: 1 month, 3 months, 6 months ]Self-reported number of days in which a participant was abstinent from tobacco after hospital discharge, by self-report, obtained from surveys done at 1 month, 3 months, and 6 months. Patient can only relapse once but it can occur at any point up to 6 months after discharge. Therefore, the data point can come from either the 1 or 3 or 6 month follow-up depending on when relapse occurred.
- Use of Smoking Cessation Treatment After Hospital Discharge [ Time Frame: 1 month, 3 months, 6 months ]Use of either FDA-approved pharmacotherapy for tobacco dependence (nicotine replacement therapy, bupropion, or varenicline), or psychosocial support (including telephone counseling, in person counseling, web-based counseling, physician counseling).
- All-cause Hospitalizations [ Time Frame: 12 months ]Self-reported admission to a hospital in the 12 months after the index hospitalization.
- All-cause Mortality [ Time Frame: 6 months ]Death from any cause in the 6 months after hospital discharge
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Cigarette smoker (smoked at least 1 cigarette in the month before hospital admission and at least 1 cigarette per day when smoking at baseline rate in the month before hospital admission)
- Counseled by hospital smoking counselor during hospital stay
- Plans to stop smoking tobacco products after hospital discharge
- Agrees to take home a supply of smoking cessation medication after discharge
- Agrees to and able to accept telephone calls after hospital discharge
- No access to a telephone or unable to communicate by telephone
- Severe psychiatric or neurologic disease precluding ability to provide informed consent and to be counseled
- Pregnant, nursing, or planning to become pregnant in next 3 months
- Unable to speak English
- Medical instability precluding study participation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01714323
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|North Shore Medical Center|
|Salem, Massachusetts, United States, 01970|
|United States, Pennsylvania|
|University of Pittsburgh Medical Center|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Nancy A Rigotti, MD||Massachusetts General Hospital|
|Responsible Party:||Nancy A. Rigotti, Professor of Medicine, Massachusetts General Hospital|
|Other Study ID Numbers:||
1R01HL111821 ( U.S. NIH Grant/Contract )
|First Posted:||October 25, 2012 Key Record Dates|
|Results First Posted:||June 8, 2018|
|Last Update Posted:||June 8, 2018|
|Last Verified:||November 2016|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Tobacco use disorder
Tobacco Use Disorder